Woodline Partners’s Definium Therapeutics DFTX Stock Holding History

Woodline Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.2M	Buy	752,792 +602,222	+400%	+$10.2M	0.05%	423
2025 Q4	$2.02M	Buy	+150,570	New	+$1.86M	0.01%	769
2025 Q3	–	Sell	-502,198	Closed	-$3.26M	–	992
2025 Q2	$3.26M	Sell	502,198 -503,000	-50%	-$3.31M	0.02%	638
2025 Q1	$5.88M	Hold	1,005,198	–	–	0.04%	462
2024 Q4	$7M	Buy	1,005,198 +2,654	+0.3%	+$18.3K	0.05%	421
2024 Q3	$5.7M	Buy	1,002,544 +1,294	+0.1%	+$9K	0.05%	376
2024 Q2	$7.22M	Buy	1,001,250 +671	+0.1%	+$5.87K	0.07%	291
2024 Q1	$9.41M	Buy	+1,000,579	New	+$5.71M	0.09%	280

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners's DFTX Position: Q1 2026 in Review

Woodline Partners increased its Definium Therapeutics (DFTX) stake by 400% in Q1 2026, buying an estimated $10.2M and bringing the position to 752,792 shares worth $14.2M. The position accounts for 0.05% of the portfolio, ranked #423.

Woodline Partners first reported a position in DFTX in Q1 2024 and has held it in 8 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Woodline Partners held 752,792 shares of Definium Therapeutics worth $14.2M as of Q1 2026.
Woodline Partners bought 602,222 Definium Therapeutics shares in Q1 2026, an estimated $10.2M.
Definium Therapeutics made up 0.05% of Woodline Partners's portfolio in Q1 2026, its #423 holding.
Woodline Partners first reported a position in Definium Therapeutics in Q1 2024 and has held it in 8 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.